Breaking News

Novartis, Legend Biotech Enter Exclusive CAR-T Therapies Agreement

Aims to advance Legend’s autologous CAR-T cell therapy candidate, LB2102, using the Novartis T-Charge platform.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Legend Biotech, a global biotechnology company, has entered into an exclusive, global license agreement with Novartis Pharma for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting DLL3, including its autologous CAR-T cell therapy candidate, LB2102. Novartis gains exclusive worldwide rights to develop, manufacture and commercialize these cell therapies, and may apply its T-Charge platform to manufacture them.   Legend Biotech is initiating clinical developm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters